Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type I Gaucher Disease: results of a 48-month longitudinal cohort study

Sims KB, Barranger J, Kaplan P, Mankin H, Packman S, Pastores GM, Rosenbloom R, Rosenthal D, Angell J, Fitzpatrick MA, Weinreb N. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type I Gaucher Disease: results of a 48-month longitudinal cohort study. Amer Society Human Genetics. 2006.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.